In vivo evaluation of a novel epitope-tagged human factor VIII-encoding adenoviral vector

Haemophilia

Volumn 5, Issue 5, 1999, Pages 340-348

  Roy, S ^a   Shirley, P S ^a   Connelly, S ^a   Andrews, J L ^a   Kayda, D B ^a   Gardner, J M ^a   Kaleko, M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adenovirus; Factor VIII; Gene therapy; Hepatocytes; Liver; Monkey

Indexed keywords

BLOOD CLOTTING FACTOR 8; EPITOPE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ARTICLE; FEMALE; HEMOPHILIA A; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; DOGS; EPITOPES; FACTOR VIII; GENETIC VECTORS; HAPLORHINI; HEMOPHILIA A; HUMANS; MICE; REFERENCE STANDARDS;

EID: 0032751649     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1999.00310.x     Document Type: Article

References (37)

1. Connelly S, Kaleko M. Gene therapy for hemophilia A. Thromb Haemost 1997; 78: 31-6.
2. Connelly S, Kaleko M. Haemophilia A gene therapy. Haemophilia 1998; 4: 380-8.
3. Smith TAG. Gene therapy for haemophilia. Exp Opin Invest Drugs 1997; 6: 1685-90.
4. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA cloned. Nature 1984; 312: 330-7.
5. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30.
6. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding antihemophiliac factor. Nature 1984; 312: 342-6.
7. Elder B, Lakich D, Gitschier J. Sequence of the murine factor VIII cDNA. Genomics 1993; 16: 374-9.
8. Healey JF, Lubin IM, Lollar P. The cDNA and derived amino acid sequence of porcine factor VIII. Blood 1996; 88: 4209-14.
9. Cameron C, Notley C, Hoyle S, et al. The canine factor VIII cDNA and 5′ flanking sequence. Thromb Haemost 1998; 79: 317-22.
10. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
11. Kaufman RJ. Biological regulation of factor VIII activity. Annu Rev Med 1992; 43: 325-39.
12. Tagliavacca L, Moon N, Dunham WR, Kaufman RJ. Identification and functional requirement of Cu (I) and its ligands within coagulation factor VIII. J Biol Chem 1997; 272: 27 428-34.
13. Hamer RJ, Koedam JA, Besser-Visser NH, et al. Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain. Eur J Biochem 1987; 166: 37-41.
14. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1998; 263: 10 451-5.
15. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 11 601-5.
16. Fay PJ, Beattie TL, Regan LM, O'Brien LM, Kaufman RJ. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalyzed proteolysis J Biol Chem 1996; 271: 6027-32.
17. Connelly S, Smith TAG, Dhir G, et al. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 1995; 6: 185-93.
18. Connelly S, Gardner JM, Lyons RM, McClelland A, Kaleko M. Sustained expression of therapeutic levels of human factor VIII in mice. Blood 1996; 87: 4671-7.
19. Connelly S, Gardner JM, McClelland A, Kaleko M. High level tissue-specific expression of functional human FVIII in mice. Hum Gene Ther 1996; 7: 183-95.
20. Connelly S, Andrews J, Gallo AM, et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 1998; 91: 3273-81.
21. Connelly S, Andrews JL, Gallo AM, et al. Evaluation of an adenoviral vector encoding full-length factor VIII in hemophiliac mice. Thromb Haemost 1999; 81: 234-9.
22. Connelly S, Mount J, Mauser A, et al. Complete shortterm correction of canine hemophilia A by in vivo gene therapy. Blood 1996; 88: 3846-53.
23. 1 cyclins. Cell 1993; 73: 1059-65.
24. Toole JJ, Pittman DD, Orr EC, et al. A large region (∼95 kDa of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986; 83: 5939-42.
25. Smith TAG, Mehaffey MG, Kayda DB, et al. Adenovirus-mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402.
26. Gorziglia MI, Kadan MJ, Yei S, et al. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 1996; 6: 4173-8.
27. Rosenfeld MA, Yoshimura K, Trapnell BC, et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-55.
28. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-509.
29. Tolstoshev P, Mittereder N, Yei S, Trapnell BC. Adenovirus vectors for gene therapy. In: Cancer Chemotherapy: Challenges for the Future. Excerpta Medica Ltd, Tokyo, 1994: 23-31.
30. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980; 209: 497-9.
31. Pittman DD, Kaufman RJ. Site directed mutagenesis and expression of coagulation factors VIII and V in mammalian cells. In Mann KG, Lorand L, eds. Methods in Enzymology, Vol. 222. Academic Press Inc., San Diego, 1993: 236-60.
32. Bi L, Lawler AM, Antonarakis SE, et al. Targeted disruption of the mouse factor VIII gene produces a model of Haemophilia A. Nature Genet 1995; 10:119-21.
33. Kolodziej PA, Young RA. Epitope tagging and protein surveillance. Math Enzymol 1991; 194: 508-19.
34. Jones C, Patel A, Griffin S, et al. Current trends in molecular recognition and bioseparation. J Chromatogr 1995; 707: 3-22.
35. Howard M, DuVall MD, Devor DC, et al. Epitope tagging permits cell surface detection of functional CFTR. Am J Physiol 1995; 269: 1565-76.
36. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 1908; 75: 1999-2004.
37. Pittman DD, Alderman EM, Tomkinson KN, et al. Biochemical. Immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993; 81: 2925-35.